LC
ORMP icon

Landaas & Company’s Oramed Pharmaceuticals ORMP Stock Holding History

Landaas & Company’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-230
Closed -$2K – 234
2018
Q2 		$2K Buy
+230
New +$1.67K ﹤0.01% 326
2018
Q1 		– Sell
-230
Closed -$2K – 228
2017
Q4 		$2K Hold
230
– – ﹤0.01% 316
2017
Q3 		$2K Buy
+230
New +$1.98K ﹤0.01% 319

Other funds holding ORMP

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Landaas & Company's ORMP Position: Q3 2018 in Review

Landaas & Company sold out of Oramed Pharmaceuticals (ORMP) in Q3 2018, closing a stake of 230 shares — an estimated $2K sold.

Landaas & Company first reported a position in ORMP in Q3 2017 and held it in 3 quarters. The position peaked at $2K in Q2 2018. 28 funds tracked by Wall St. Rank hold ORMP as of Q3 2018.

  • Landaas & Company reported no remaining Oramed Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Landaas & Company sold 230 Oramed Pharmaceuticals shares in Q3 2018, an estimated $2K.
  • Landaas & Company first reported a position in Oramed Pharmaceuticals in Q3 2017 and held it in 3 quarters.
  • Landaas & Company's Oramed Pharmaceuticals position peaked at $2K in Q2 2018.
  • 28 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2018.

Based on Landaas & Company's 13F filing for Q3 2018, filed 14 Nov 2018.